RNS Number : 8680G
Intelligent Ultrasound Group PLC
24 July 2023
 

 

24 July 2023

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.

 

 

Intelligent Ultrasound Group plc

(the "Group")

 

Trading update

 

Intelligent Ultrasound Group plc reports positive trading period in H1

 

Intelligent Ultrasound Group plc (AIM: IUG) ("Intelligent Ultrasound" or "the Group"), the 'classroom to clinic' ultrasound company specialising in artificial intelligence (AI) software and simulation, today provides a trading update for the six months to 30 June 2023.

 

Financial highlights:

·    The Group expects to report that revenue for the period to 30 June 2023 has grown by 3% to £6.1m (H1 2022: £5.9m)

H1 2022 revenue figures included £1.4m of one-off orders from the NHS in the UK, so on an adjusted like-for-like basis, revenue in H1 2023 is expected to have increased by 35% (H1 2022 adjusted: £4.5m)

·      The Group's clinical AI products continue to gain traction and revenues are expected to have more than doubled to £0.7m (H1 2022: £0.3m)

·    Cash at bank on 30 June 2023 was £3.4m (31 December 2022: £7.2m), impacted by working capital seasonality in H1

·    Cash utilisation in H2 is expected to be materially lower and the Group remains on target to reach profitability with its current cash

 

The company will publish its half-year results in August.

 

 

For further information, please contact:

 

Intelligent Ultrasound Group plc 

www.intelligentultrasound.com

Stuart Gall, CEO 

Tel: +44 (0)29 2075 6534 



Helen Jones, CFO


 


 


Cenkos Securities - Nominated Advisor and Broker


Giles Balleny/Max Gould (Corporate Finance)

Tel: +44 (0)20 7397 8900 

Michael Johnson/Julian Morse (Sales) 




TB Cardew - PR Advisors

Ed Orlebar

Intelligentultrasound@tbcardew.com

Tel: +44 (0)7738 724630

Allison Connolly

                          Tel: +44 (0)7587 453955

Emma Pascoe-Watson

Tel: +44 (0)7774 620415

Hero Kurzeja

  Tel: +44 (0)7827 130430

 

 

About Intelligent Ultrasound Group

 

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

 

Real-time hi-fidelity ultrasound education and training through simulation.  Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,500 simulators have been sold to over 750 medical institutions around the world.

 

Clinical AI software

 

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

 

www.intelligentultrasound.com

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA, but is not available for sale in any other territory requiring government approval for this type of product.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEDDFILFIV